类风湿关节炎患者因颌骨药物相关性骨坏死导致脓毒症：一例报告及临床启示
Medication-related osteonecrosis of the jaw leading to sepsis in a patient with rheumatoid arthritis: A case report and clinical implications.
作者信息
Iwasaki Kazuhiko, Okazaki Akihito
机构信息
Department of Internal Medicine Kaga Medical Center Kaga Japan.
Department of Respiratory Medicine Kanazawa University Graduate School of Medical Sciences Kanazawa Japan.
出版信息
Clin Case Rep. 2023 Jun 17;11(6):e7588. doi: 10.1002/ccr3.7588. eCollection 2023 Jun.
KEY CLINICAL MESSAGE
Chronic use of bisphosphonates, in combination with immunosuppressive therapy, increases the risk of jaw osteonecrosis. When sepsis occurs in patients receiving bisphosphonate, osteonecrosis of the jaw should be considered a potential source of infection.
ABSTRACT
Reports of medication-related osteonecrosis of the jaw (MRONJ) accompanied by sepsis are limited. A 75-year-old female patient with rheumatoid arthritis, receiving treatment with bisphosphonate and abatacept, developed sepsis secondary to MRONJ. When sepsis occurs in patients receiving bisphosphonate, osteonecrosis of the jaw should be considered a potential source of infection.
关键临床信息
长期使用双膦酸盐类药物并联合免疫抑制治疗会增加颌骨坏死的风险。接受双膦酸盐治疗的患者发生脓毒症时，应考虑颌骨坏死是潜在的感染源。
摘要
关于伴有脓毒症的药物相关性颌骨坏死（MRONJ）的报道有限。一名75岁的类风湿关节炎女性患者，正在接受双膦酸盐和阿巴西普治疗，继发于MRONJ而发生了脓毒症。接受双膦酸盐治疗的患者发生脓毒症时，应考虑颌骨坏死是潜在的感染源。
Zotero 插件